- Home
- COCH vs ATHA Comparison
COCH vs ATHA Comparison
Compare COCH & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | ATHA |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 18.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | COCH | ATHA |
|---|---|---|
| Price | $0.84 | $4.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 541.8K | 26.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,000.00 | N/A |
| Revenue This Year | $3.66 | N/A |
| Revenue Next Year | $31.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $2.20 |
| 52 Week High | $2.32 | $6.79 |
Technical Indicators
Market Signals| Indicator | COCH | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 55.16 |
| Support Level | $0.66 | $4.31 |
| Resistance Level | $0.87 | $4.81 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 86.84 | 47.12 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.